Form 4: Cue Biopharma CEO Daniel Passeri Acquires 450,000 Stock Options
SEC Form 4 Filing
Cue Biopharma's CEO, Daniel Passeri, reports the acquisition of 450,000 stock options exercisable over time.
Summary
- Daniel R Passeri, CEO of Cue Biopharma, Inc., filed a Form 4 on March 25, 2025, reporting changes in beneficial ownership.
- The report indicates that Passeri acquired 450,000 stock options on March 21, 2025, with an exercise price of $0.99.
- These options become exercisable in eight equal semi-annual installments starting September 21, 2025, and expire on March 20, 2035.
- Passeri directly owns these derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing indicating stock option grants to the CEO. It suggests alignment of interests but doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's success.
Key Dates
| Date | Description |
|---|---|
| 03/21/2025 | Date of transaction: CEO acquired stock options. |
| 03/25/2025 | Date of Form 4 filing. |
| 09/21/2025 | First vesting date for the stock options. |
| 03/20/2035 | Expiration date of the stock options. |
Keywords
stock options, Form 4, beneficial ownership, Cue Biopharma, Daniel Passeri, CEO, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.